Newsroom

MedinCell to present at the Evercore ISI 2024 Emerging Biotech Conference

February 15, 2024

February 15, 2024

MedinCell’s partner Teva provides guidance for UZEDY in 2024 and an update on olanzapine LAI (mdc-TJK)

January 31, 2024

January 31, 2024

Teva announces recruitment completion of phase 3 clinical study of mdc-TJK

January 9, 2024

January 9, 2024

Jefferies initiates MedinCell’s coverage with a “Buy” recommendation

January 4, 2024

January 4, 2024

Half-Year results (April 2023 – September 2023)

December 19, 2023

December 19, 2023

Videoconference • Half-Year results

December 19, 2023

In Vitro and In Vivo Hydrolytic Degradation Behaviors of a Drug-Delivery System Based on the Blend of PEG and PLA Copolymers

November 27, 2023

November 27, 2023

MedinCell applauds Teva and Royalty Pharma collaboration to further accelerate olanzapine LAI program

November 13, 2023

November 13, 2023

MedinCell at the 2023 Jefferies Global Healthcare Conference -London, 14-16 November

November 6, 2023

November 6, 2023

MedinCell and the European Investment Bank (EIB) have replaced a financial covenant of their ongoing loan agreement to better fit with MedinCell business model

October 3, 2023

October 3, 2023

MedinCell partner Teva announces successful launch of UZEDY™

September 12, 2023

2023 General Meeting (French)

September 12, 2023